中国肺癌杂志2017，Vol.20Issue(1)：66-72,7.DOI:10.3779/j.issn.1009-3419.2017.01.10
晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展
Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer
张权 1张树才1
作者信息
- 1. 101149北京，首都医科大学附属北京胸科医院肿瘤内科
- 折叠
摘要
Abstract
Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. hTis area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. hTis review aimed to summarize the advanced develop-ments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC.关键词
肺肿瘤/靶向治疗/ALKKey words
Lung neoplasms/Targeted therapy/ALK引用本文复制引用
张权,张树才..晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展[J].中国肺癌杂志,2017,20(1):66-72,7.
